The rise of drug-resistant tinea infections is challenging healthcare providers. The emergence of new species such as Trichophyton indotineae, resistant T rubrum, and TMVII has led to difficulties in diagnosis and treatment. Public health officials are working to raise awareness and provide resources for providers to track and report cases. Challenges include a lack of testing facilities and data, as well as payer pushback over longer therapeutic courses. The limited arsenal of antifungals available in the United States is a concern, but promising drugs are in development. A coordinated effort involving various healthcare providers is needed to address the challenge of emerging complex dermatophytosis.
Source link